Viking Therapeutics, Inc. (VKTX)의 가격은 얼마입니까?

Viking Therapeutics, Inc. (VKTX)의 가격은 $34.24입니다.

Viking Therapeutics, Inc. (VKTX)의 시가 총액은 무엇입니까?

Viking Therapeutics, Inc. (VKTX)의 시가 총액은 $3.99B입니다.

Viking Therapeutics, Inc. (VKTX) 수익

Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.

연도	매출	변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.

연도

매출

변화

제공된 날짜에 대한 데이터가 충분하지 않습니다.

회사	매출	매출 차이	국가
Vertex Pharmaceuticals Incorporated VRTX.US	$12.62B	-	US
Argenx SE ARGX.US	$6.02B	-	NL
Moderna, Inc. MRNA.US	$2.23B	-	US
CSL Limited CSL.AX	$15.74B	-	AU
Lonza Group AG LONN.SW	-	-	CH

회사

매출

매출 차이

국가